JP2024505128A5 - - Google Patents
Info
- Publication number
- JP2024505128A5 JP2024505128A5 JP2023540516A JP2023540516A JP2024505128A5 JP 2024505128 A5 JP2024505128 A5 JP 2024505128A5 JP 2023540516 A JP2023540516 A JP 2023540516A JP 2023540516 A JP2023540516 A JP 2023540516A JP 2024505128 A5 JP2024505128 A5 JP 2024505128A5
- Authority
- JP
- Japan
- Prior art keywords
- mass
- volume
- cancer
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/141601 | 2020-12-30 | ||
| CN2020141601 | 2020-12-30 | ||
| PCT/CN2021/092485 WO2022142053A1 (en) | 2020-12-30 | 2021-05-08 | Formulations of anti-cd73 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505128A JP2024505128A (ja) | 2024-02-05 |
| JP2024505128A5 true JP2024505128A5 (https=) | 2024-05-17 |
Family
ID=82258959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540516A Pending JP2024505128A (ja) | 2020-12-30 | 2021-05-08 | 抗ｃｄ７３抗体の製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240101698A1 (https=) |
| EP (1) | EP4271410A4 (https=) |
| JP (1) | JP2024505128A (https=) |
| KR (1) | KR20230127292A (https=) |
| CN (1) | CN116615458A (https=) |
| AU (1) | AU2021415180A1 (https=) |
| CA (1) | CA3203441A1 (https=) |
| WO (1) | WO2022142053A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119744177A (zh) * | 2023-07-24 | 2025-04-01 | 石药集团巨石生物制药有限公司 | 重组人源化抗cd73单克隆抗体的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SV2007002227A (es) * | 2004-09-10 | 2007-03-20 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637 |
| JP5933975B2 (ja) * | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| CN102512384B (zh) * | 2011-12-29 | 2014-11-26 | 嘉和生物药业有限公司 | 一种冻干剂型蛋白组合物及其制备方法 |
| MX2018003298A (es) * | 2015-09-22 | 2018-06-20 | Pfizer | Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo. |
| WO2017189433A1 (en) * | 2016-04-25 | 2017-11-02 | Medimmune, Llc | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |
| CA3045376C (en) * | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| US20210054079A1 (en) * | 2018-04-25 | 2021-02-25 | Medimmune Limited | Formulations of human anti-pd-li antibodies |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| CN111686247B (zh) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
-
2021
- 2021-05-08 WO PCT/CN2021/092485 patent/WO2022142053A1/en not_active Ceased
- 2021-05-08 US US18/270,472 patent/US20240101698A1/en active Pending
- 2021-05-08 EP EP21912814.7A patent/EP4271410A4/en active Pending
- 2021-05-08 KR KR1020237025806A patent/KR20230127292A/ko active Pending
- 2021-05-08 CN CN202180079028.7A patent/CN116615458A/zh active Pending
- 2021-05-08 AU AU2021415180A patent/AU2021415180A1/en active Pending
- 2021-05-08 CA CA3203441A patent/CA3203441A1/en active Pending
- 2021-05-08 JP JP2023540516A patent/JP2024505128A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113651831A (zh) | 生物活性物偶联物及其制备方法和用途 | |
| JP2019517549A5 (https=) | ||
| TW202019487A (zh) | 抗體-藥物結合物及微管蛋白抑制劑之組合 | |
| JP2019508013A5 (https=) | ||
| JP2019503349A5 (https=) | ||
| JP2021513540A5 (https=) | ||
| JP2023507190A5 (https=) | ||
| JP2025081512A (ja) | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） | |
| JP2020500834A5 (https=) | ||
| JP2022543062A5 (https=) | ||
| JP2022513684A5 (https=) | ||
| JP2023505217A5 (https=) | ||
| JP2019524713A5 (https=) | ||
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2021531255A5 (https=) | ||
| JP2019532970A5 (https=) | ||
| US12053530B2 (en) | Plectin-1 binding antibodies and uses thereof | |
| JP2025515092A5 (https=) | ||
| JP2003505432A (ja) | 抗ｅｐ−ｃａｍ抗体と化学療法剤との組合せ | |
| JP2024514277A5 (https=) | ||
| JP2024505128A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| JP2021518348A5 (https=) | ||
| CN115698076A (zh) | 用于治疗肿瘤的药物 |